<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="455">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667442</url>
  </required_header>
  <id_info>
    <org_study_id>Nanomix CVAG-202</org_study_id>
    <nct_id>NCT04667442</nct_id>
  </id_info>
  <brief_title>Investigational Performance Evaluation of the Nanomix eLab® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects</brief_title>
  <official_title>An Investigational Performance Evaluation of the Nanomix eLab® COVID-19 Rapid Antigen Panel With Samples From COVID-19 Positive and Negative Human Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanomix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanomix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective samples will be collected to evaluate the agreement between a EUA RT-PCR test as&#xD;
      the comparator method against the Nanomix eLab® system.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate clinical agreement between an EUA RT-PCR methodology and the Nanomix eLab® COVID-19 Rapid Antigen Panel</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>An analysis of the result from subjects who have been or will be tested by EUA RT-PCR will be performed to establish the sensitivity by positive percent agreement (PPA) and the specificity by negative percent agreement (NPA) of the Nanomix eLab® COVID-19 Rapid Antigen Panel and a confirmatory EUA RT-PCR method.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>EUA RT-PCR positive</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>EUA RT-PCR negative</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Nanomix eLab® COVID-19 Rapid Antigen Panel (non-interventional)</intervention_name>
    <description>COVID-19 Rapid Antigen Diagnostic Test</description>
    <arm_group_label>EUA RT-PCR negative</arm_group_label>
    <arm_group_label>EUA RT-PCR positive</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasal sample (without cells/ RNA/DNA) will be aliquoted and stored at Sponsor for potential&#xD;
      future analysis/ projects.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include both symptomatic and asymptomatic subjects. Although to&#xD;
        enrich for COVID-19 positive subjects, the study will preferentially identify and enrolled&#xD;
        subjects who have been or will be tested by EUA RT-PCR including those who are symptomatic&#xD;
        or hospitalized with symptoms, specifically those within 7-days of symptom onset that meet&#xD;
        the study enrollment inclusion and exclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  Symptomatic or asymptomatic&#xD;
&#xD;
          -  The EUA RT-PCR sample must be collected within one (1) day of the sample collected for&#xD;
             testing by the Nanomix eLab® COVID-19 Rapid Antigen Panel.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects without both a valid EUA RT-PCR test result and a valid Nanomix eLab®&#xD;
             COVID-19 Rapid Antigen results will be excluded&#xD;
&#xD;
          -  Subjects not being able to provide consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tina Landess</last_name>
    <role>Study Director</role>
    <affiliation>Nanomix</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tina Landess</last_name>
    <phone>(510) 428-5300</phone>
    <email>tlandess@nano.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Ludvigson</last_name>
    <phone>(510) 428-5300</phone>
    <email>DLudvigson@nano.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nanomix</name>
      <address>
        <city>Emeryville</city>
        <state>California</state>
        <zip>94608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Ludvigson</last_name>
      <phone>510-428-5300</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

